IRVINE, CA / ACCESSWIRE / August 7, 2017 / Khang & Khang LLP (the"Firm") announces a securities class action lawsuit against Roche Holding AG ("Roche Holding" or the "Company") (OTCQX: RHHBY). Investors, who purchased or otherwise acquired Roche Holding shares from March 2, 2017 through June 5, 2017, inclusive (the "Class Period"), are encouraged to contact the Firm by the August 7, 2017 lead plaintiff motion deadline.
If you purchased Roche Holding shares during the Class Period, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 4000 Barranca Parkway, Suite 250, Irvine, CA 92604, by telephone at (949) 419-3834, or by e-mail at joon@khanglaw.com.
There has been no class certification in this case yet, and until certification occurs, you are not represented by an attorney. You may also choose to take no action and remain a passive class member.
According to the lawsuit, throughout the Class Period, Roche Holding issued materially false and/or misleading statements and/or failed to disclose material information, specifically that the combination of the Company’s breast cancer drug, Perjeta, and its older treatment, Herceptin, is only slightly more effective than Herceptin alone in preventing breast cancer, and has a higher rate of side effects. Following this news, Roche Holding’s share price declined materially, which harmed investors according to the Complaint.
If you want to learn more about this lawsuit, or if you have questions about this notice or your rights, please contact Joon M. Khang, a prominent litigator for nearly two decades, by telephone at (949) 419-3834, or by e-mail at joon@khanglaw.com.
This press release may be considered Attorney Advertising in certain jurisdictions.
Contact:
Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com
SOURCE: Khang & Khang LLP
ReleaseID: 471425
